Cardiotoxicity Related to Long-Term Trastuzumab Therapy in Metastatic Breast Cancer: The Potential Role of Treatment Duration and Cardiac Risk Factors-Reference-Cited by-同舟云学术

Cardiotoxicity Related to Long-Term Trastuzumab Therapy in Metastatic Breast Cancer: The Potential Role of Treatment Duration and Cardiac Risk Factors

Published:2015-03-19 Issue:3 Volume:21 Page:318-321
ISSN:1075-122X
Container-title:The Breast Journal
language:en
Short-container-title:Breast J

Author:

Pistilli Barbara¹,Marcellusi Andrea²³,Latini Luciano¹,Accardi Roberto⁴,Ferretti Benedetta⁵,Benedetti Giovanni¹

Affiliation:

1. Oncology Unit; Macerata Hospital; Macerata Italy

2. Centre for Health Economics and Management (CHEM); Faculty of Economics; Tor Vergata University; Rome Italy

3. Department of Statistics; University of Rome “Sapienza”; Rome Italy

4. Cardiology Hemodinamic Unit; Macerata Hospital; Macerata Italy

5. Oncology Unit; San Severino Hospital; San Severino Italy

Publisher

Hindawi Limited

Subject

Oncology,Surgery,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/tbj.12412/fullpdf

Reference17 articles.

1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

2. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer;Burstein;J Clin Oncol,2001

3. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study;Minckwitz;J Clin Oncol,2009

4. Cardioncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors;Albini;Future Cardiol,2011

5. HERA TRIAL: 2 years vs 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow-up;Goldhirsch;Cancer Res,2012

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018;Breast Cancer Research and Treatment;2022-07-22

2. Cardiac monitoring during trastuzumab therapy in metastatic breast cancer: early incidence of cardiac dysfunction;Monaldi Archives for Chest Disease;2022-02-17

3. Chemotherapy-related cardiac dysfunction;Current Opinion in Cardiology;2017-03

4. Trastuzumab cardiotoxicity: from clinical trials to experimental studies;British Journal of Pharmacology;2016-11-25

5. Observational study of trastuzumab-related cardiotoxicity in early and metastatic breast cancer;Journal of Oncology Pharmacy Practice;2016-03-15